Children With Leukodystrophy
Conditions
Brief summary
Leukodystrophies are heterogeneous genetic disorders characterized by the selective involvement of white matter in the central nervous system (CNS) (1, 2). Inherited leukodystrophies are diseases of the myelin, including abnormal myelin development, hypomyelination, or degeneration of myelin (3, 4). Most of these disorders fall into one of three categories; lysosomal storage diseases, peroxisomal disorders, and diseases caused by mitochondrial dysfunction and each leukodystrophy has distinctive clinical, biochemical, pathologic, and radiologic features (5).
Interventions
DEVICEMRI
MRI pattern in children with Leukodystrophy
Sponsors
Sohag University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to 18 Years
Healthy volunteers
Yes
Inclusion criteria
* The patients fulfilling all the following criteria will be included: 1. Age ≤ 18 years. 2. The presence of typical clinical, biochemical, and neuroimaging features of leukodystrophies.
Exclusion criteria
* 1- Children who have coexistent genetic disorders. 2- Children who have cerebral malformations. 3- History of perinatal asphyxia. 4- History of head trauma or intracranial hemorrhage. 5- Acquired CNS myelin disorders, such as multiple sclerosis and related acquired demyelinating processes, infectious and post-infectious white matter damage, toxic injuries and non-genetic vascular insults.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| White matter changes in MRI | 2 years | Brain MRI of all patients will be systematically reviewed, particularly Sagittal T1, Axial T1, T2-weighted and fluid-attenuated inversion-recovery (FLAIR) sequences. Other sequences will be also reviewed if available, such as MR spectroscopy (MRS) (for mitochondrial disorders or Canavan disease to investigate abnormalities in lactate or N-acetyl aspartate (NAA) respectively), and diffusion-weighting (useful in disorders such as AARS2-related leukoencephalopathy). |
| Biochemical changes | 2 years | 1. Arylsulfatase A levels can be measured in the leukocytes if suspected Metachromatic Leukodystrophy. 2. Galactocerebrosidase (GALC) enzyme level for Krabbe's Disease. 3. Plasma VLCFAs for Adrenoleukodystrophy. 4. NAA levels in the urine for Canavan's Disease. 5. Beta galactosidase in leukocytes deficient in cases of infantile GM1 gangliosidosis &Hexosaminidase for Tay Sachs disease. 6. Plasma FSH ,LH markedly reduced in cases of 4 H (Hypomyelination, hypodontia and hypogonadotropic hypogonadism syndrome). 7. Genetic testing for certain diseases |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Electrophysiological changes | 2 years | including nerve conduction studies and electromyography will be useful in identifying peripheral nerve involvement (e.g., in AMN, MLD, Krabbe) or myopathy with or without a neuropathy (e.g., in mitochondrial diseases) or metachromatic leukodystrophy. Moreover, electroencephalographic data will be assessed, particularly in patients with seizures. |
| Tandem mass spectrometry (MS/MS) finding | 2 years | We will obtain patients' blood samples on a Glutheric card, Acylcarnitines and amino acids will be analysed using ACQUTIY TQD Tandem quadrupole UPLC/MS/MS with apositive electrospray ionization prope according to the manufacturer's instructions. |
| Urinary organic acid analysis | 2 years | by GC/MS using agilent 7890 and 5975 systems. Results will be calculated in mol/mmol creatinine using acalipration curve of the organic acid of interest that will be processed under the same conditions. |
Contacts
Primary ContactNagat Mohamed, Master
Backup ContactAbdelraheem Abdrabu, Professor
Outcome results
None listed